Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Jul. 2018 11 Hacking Dermatology Selects 5 Finalist Teams for Incubation

Hacking Dermatology is an initiative that aims to bring interdisciplinary teams together to solve the important challenges facing patients with skin disease. It is led and supported by a consortium of academic, non-profit, and industry partners, including Hacking Medicine Institute (HMi), LEO Pharma, Advancing Innovation in Dermatology (AID), MIT Hacking Medicine, and the Lahey Medical […]

Read more
Apr. 2018 12 LEO Science & Tech Hub Enters Collaboration with Dina Katabi MIT, CSAIL to Explore the Use of Radio Signals for Quantification of Itch

LEO Science & Tech Hub, the Boston based R&D unit of LEO Pharma, has entered into a collaboration with Dina Katabi and MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL). Together they will explore the potential of the MIT group’s Emerald system to quantify scratching behavior. The Emerald technology uses the reflection of radio signals to measure human […]

Read more